



		CDR2	FR3
		5	6 7 8
AHM	(SEQ ID NO: 130)	0123456	78901234567890123456789012345678
HuSG	I (SEQ ID NO: 131)	SASNRYT	GVPDRITGSGSGTDFTFTISSVQAEDLALYYC
REI	(SEQ ID NO: 132)		GVPSRFSGSGSGTDFTLTITSSLPEDFATYYC
RVLa	(SEQ ID NO: 133)	-----	GVPSRFSGSGSGTDFTFTITSSLPEDIATYYC
RVLb	(SEQ ID NO: 134)	-----	-----Y-----

		CDR3	FR4
		9	10
AHM	(SEQ ID NO: 130)	901234567	8901234567
HuSG	I (SEQ ID NO: 131)	QQHYSTPFT	FGSGTKLEIK
REI	(SEQ ID NO: 132)		FGQGTKVEIK
RVLa	(SEQ ID NO: 133)	-----	FGQGTKVEIK
RVLb	(SEQ ID NO: 134)	-----	-----

On page 62, delete Table 4, and replace this with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Table 4

The amino acid sequence of the H chain V region (1)

		FRI	CDR1	FR2
		1 2 3		4
AHM	(SEQ ID NO: 135)	123456789012345678901234567890	12345	67890123456789
HuSGI	(SEQ ID NO: 136)	QVQLQQSGAELARPGASVKLSCKASGYTFT	PYWMQ	WVKQRPGQGLEWIG
HG3	(SEQ ID NO: 137)	EVQLVQSGADVKKPGXSXVVSCKASGYTFS		WVRQAPGXGLDWVG
RVHa	(SEQ ID NO: 138)	QVQLVQSGAEVKKPGASVKVSCKASGYTFN		WVRQAPGQGLEWMG
RVHb	(SEQ ID NO: 139)	-----T	-----	-----
RVHc	(SEQ ID NO: 140)	-----T	-----	-----
RVHd	(SEQ ID NO: 141)	-----T	-----	-----
RVHe	(SEQ ID NO: 142)	-----T	-----	-----
RVHf	(SEQ ID NO: 143)	-----T	-----	-----
RVHg	(SEQ ID NO: 144)	-----T	-----	-----R-----
RVHh	(SEQ ID NO: 145)	-----T	-----	-----
RVHi	(SEQ ID NO: 146)	-----T	-----	-----
RVHj	(SEQ ID NO: 147)	-----T	-----	-----
RVHk	(SEQ ID NO: 148)	-----T	-----	-----
RVHl	(SEQ ID NO: 149)	-----T	-----	-----
RVHm	(SEQ ID NO: 150)	-----T	-----	-----
RVHn	(SEQ ID NO: 151)	-----T	-----	-----
RVHo	(SEQ ID NO: 152)	-----T	-----	-----
RVHp	(SEQ ID NO: 153)	-----T	-----	-----
RVHq	(SEQ ID NO: 154)	-----T	-----	-----
RVHr	(SEQ ID NO: 155)	-----T	-----	-----

Table 5

On page 63, delete Table 5, and replace this with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

B3

	CDR2	FR3
	5 6	7 8 9
AHM (SEQ ID NO: 156)	012A3456789012345	67890123456789012ABC345678901234
HuSGI (SEQ ID NO: 157)	SIFPGDGDTRYSQKFKG	KATLTADKSSSTAYMQLSILAFEDSAVYYCAR
HG3 (SEQ ID NO: 158)		RVXTXDXSXNTAYMELSSLRSEDVAVYYCAR
RVHa (SEQ ID NO: 159)	-----	RVTMTRDTSTSTVYMELESLRSEDVAVYYCAR
RVHb (SEQ ID NO: 160)	-----	-----A-----
RVHc (SEQ ID NO: 161)	-----	K-----A-----
RVHd (SEQ ID NO: 162)	-----	-----A-K-----
RVHe (SEQ ID NO: 163)	-----	K-----A-K-----
RVHf (SEQ ID NO: 164)	-----	-A-L-A-----
RVHg (SEQ ID NO: 165)	-----	-A-L-A---S--A-----
RVHh (SEQ ID NO: 166)	-----	-----A-----
RVHi (SEQ ID NO: 167)	-----	K---A---S--A-----
RVHj (SEQ ID NO: 168)	-----	K---A---S--A-----AF-----
RVHk (SEQ ID NO: 169)	-----	KA-L-A---S--A-----
RVHl (SEQ ID NO: 170)	-----	K---A---S==A--Q-----
RVHm (SEQ ID NO: 171)	-----	K---A---S--A--Q--1-----
RVHn (SEQ ID NO: 172)	-----	K---A---S--A--Q--1-----S-----
RVHo (SEQ ID NO: 173)	-----	K---A---S--A-----1-----
RVHp (SEQ ID NO: 174)	-----	K---A---S--A-----S-----
RVHq (SEQ ID NO: 175)	-----	-----A-----A-----
RVHr (SEQ ID NO: 176)	-----	-----A--S-----
	-----	-----A-K-----A-----

On page 64, delete Table 6, and replace this with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Table 6

B4

	CDR3	FR4
	10	11
AHM (SEQ ID NO: 177)	57890ABJK12	34567890123
HuSGI (SEQ ID NO: 178)	GLRRGGYYFDY	WGQGTTLTVSS
JH6 (SEQ ID NO: 179)	-----	WGQGTTLTVSS
RVHa (SEQ ID NO: 180)	-----	WGQGTTLTVSS
RVHb (SEQ ID NO: 181)	-----	-----
RVHc (SEQ ID NO: 182)	-----	-----
RVHd (SEQ ID NO: 183)	-----	-----
RVHe (SEQ ID NO: 184)	-----	-----
RVHf (SEQ ID NO: 185)	-----	-----
RVHg (SEQ ID NO: 186)	-----	-----
RVHh (SEQ ID NO: 187)	-----	-----
RVHi (SEQ ID NO: 188)	-----	-----
RVHj (SEQ ID NO: 189)	-----	-----
RVHk (SEQ ID NO: 190)	-----	-----
RVHl (SEQ ID NO: 191)	-----	-----
RVHm (SEQ ID NO: 192)	-----	-----

B4

RVHn	(SEQ ID NO: 193)	-----	-----
RVHo	(SEQ ID NO: 194)	-----	-----
RVHp	(SEQ ID NO: 195)	-----	-----
RVHq	(SEQ ID NO: 196)	-----	-----
RVHr	(SEQ ID NO: 197)	-----	-----

On page 72, delete Table Design of V Region of Natural Humanized Antibody, and replace this with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Design of V region of Natural Humanized Antibody

A) L chain

	FR1	2	CDR1	FR2	CDR2
HM1.24 (SEQ ID NO: 130)	12345678901234567890123	45678901234	567890123456789	0123456	
HuSG I (SEQ ID NO: 131)	DIVMTQSHKFMSTSVGDRVSITC	KASQDVNTAVA	WYQQKPGQSPKLLIY	SASNRYT	
REI (SEQ ID NO: 132)	DIQMTQSPSSLSASVGDRTITC		WYQQKPGKAPKLLIY		
Primary design (RVLa (SEQ ID NO: 133))	DIQMTQSPSSLSASVGDRTITC		WYQQKPGKAPKLLIY		
Secondary design (SEQ ID NO: 133)					
	FR3	7	CDR1	FR2	
	6	8	9	10	
HM1.24 (SEQ ID NO: 130)	78901234567890123456789012345678	GVPDRITGSGGTDFTTISVQAEALALYYC	901234567VA	8901234567	
HuSG I (SEQ ID NO: 131)	GVPSRFSGSGGTDFTLTISLQPEDFATYYC		QOHYSTPFT	FGSGTKLEIK	
REI (SEQ ID NO: 132)	GVPSRFSGSGGTDFTLTISLQPEDFATYYC			FGQGTKVEIK	
Primary design (RVLa (SEQ ID NO: 133))				FGQGTKVEIK	
Secondary design (SEQ ID NO: 133)					

On page 73, delete Table Design of V Region of Natural Humanized Antibody, and replace this with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

Design of V region of Natural Humanized Antibody

B) H chain

	FR1	CDR1	FR2	CDR2
HM1.24 (SEQ ID NO: 198)	123456789012345678901234567890	12345	67890123456789	012A3456789012345
HuSG I (SEQ ID NO: 199)	QVQLQSGAELARPGASVKLSCKASGYTFT	PYWMQ	WVKQRPQGLEWIG	SIFPGDTRYSGKFKG
HG3 (SEQ ID NO: 200)	EVQLVQSGADVKKPGXSVXVCKASGYTFS	---	WVRQAPGXGLDWVG	---
Primary design (RVHR (SEQ ID NO: 201)	QVQLVQSGAEVKKPGASVKVCKASGYTFN	---	WVRQAPQGLEWVG	---
Secondary design (2 nd RVH) (SEQ ID NO: 202)	-----T	---	---	---

B6

	FR3	CDR3	FR2
HM1.24 (SEQ ID NO: 198)	67890123456789012ABC345678901234	57890ABJK12	34567890123
HuSG I (SEQ ID NO: 199)	KATLTADKSSSTAYMQLSILAFEDSAVYYCAR	GLRRGGYYFDY	WGQGTTLTVSS
HG3 (SEQ ID NO: 200)	RVTXTDXSXNTAYMELSSLRSEDTAVYYCAR	---	WGQGTTVTVSS
Primary design (RVHR (SEQ ID NO: 201)	RVTMTTRDTSTSTVYMEELSSLRSEDTAVYYCAR	---	---
Secondary design (2 nd RVH) (SEQ ID NO: 202)	-----A-K---A	---	---
	---I-A-K---A	---	---

On page 74, delete line 23 and replace this with the following in accordance with 37 C.F.R. § 1.121. A marked up version showing changes is attached:

b1
FR3 of primary design antibody (SEQ ID NO: 203)